

# 15<sup>th</sup> European Lupus Meeting

Lisbon, Portugal  
4 - 7 March 2026

PRELIMINARY  
PROGRAMME





## WELCOME MESSAGE

# Welcome to the 15th European Lupus Meeting!

Dear Colleagues,

We are thrilled to invite you to the **15th European Lupus Meeting**, taking place in the beautiful city of **Lisbon, Portugal**, from **March 4th to 7th, 2026**.

This Congress, organized by SLEuro - The European Lupus Society, will bring together leading European and international experts, clinicians, patients, researchers, and stakeholders from around the globe.

**Lisbon** offers appropriate conference infrastructure and services that support the educational objectives of the event, as well as opportunities for professional interaction in a structured setting.

At the **15th European Lupus Meeting**, we will explore the latest advancements in basic and clinical research, best practices, and innovative therapies for **systemic lupus erythematosus and related conditions**. Participants can look forward to engaging sessions featuring invited talks, lively debates, fishbowl discussions, and both oral and poster presentations.

We are particularly eager to welcome **young researchers and clinicians** to the 15th European Lupus Meeting. Fresh perspectives and innovative ideas are essential for advancing our understanding and management of lupus, ultimately improving patient outcomes.

Let's work together to make this meeting an unforgettable and impactful experience.

We look forward to welcoming you to Lisbon!

**Luís Inês & Maria José Santos**

Congress Chairs

SLEuro - The European Lupus Society



## EUROPEAN LUPUS SOCIETY – SLEuro

The European Lupus Meeting is a biennial initiative of the SLEuro.

The European Lupus Society (SLEuro) was founded on 30th September 2016 in Venice (Italy) few days before the 10th European Lupus Meeting 2016.

Ongoing developments in compliance and transparency as well as the need of a solid infrastructure for European Lupus meetings and community, called for the foundation of a new association: SLEuro.

The Society pursues the following goals: building up a community of clinicians and researchers interested in SLE with special focus to engage younger physicians in the field; promoting and coordinating the organization of research and educational meetings on SLE and related syndromes; promoting equal access to best standard of care for SLE patients across Europe and facilitating research projects and clinical trials in SLE.

Find out more at [www.sleuro.org](http://www.sleuro.org)

## EXECUTIVE COMMITTEE

### President

**Luís P. Sousa Inês**, Coimbra (PT)

### Past President

**Laurent Arnaud**, Strasbourg (FR)

### President Elect

**Ioannis Parodis**, Stockholm (SE)

### General Secretary

**Edward Vital**, Leeds (UK)

### Treasurer

**Andrea Doria**, Padua (IT)

### Members

**Francesca Faustini**, Stockholm (SE)

**Mariele Gatto**, Turin (IT)

**Karoline Lerang**, Oslo (NO)

**Lars Rönnblom**, Uppsala (SE)

**Y.K. Onno Teng**, Leiden (NL)

**Anne Troldborg**, Aarhus (DK)

## SLEURO SECRETARIAT



## CONGRESS COMMITTEE

### CONGRESS CHAIRS

Prof. **L. Sousa Inês**, Coimbra (PT)  
Prof. **M.J. Santos**, Almada (PT)

### LOCAL SCIENTIFIC COMMITTEE

**C. Vasconcelos**, Porto (PT)  
**P. Costa Reis**, Lisbon (PT)  
**M. Gonçalo**, Coimbra (PT)  
**D. Jesus**, Leiria (PT)  
**P. Oliveira**, Coimbra (PT)  
**S. Silva Ribeiro**, Lisbon (PT)

### PAST CHAIRS

**D. Boumpas**, Athens (GR)  
**S. Bombardieri**, Pisa (IT)  
**R. Cervera**, Barcelona (ES)  
**N. Costedoat-Chalumeau**, Paris (FR)  
**A. Doria**, Padua (IT)  
**F. Houssiau**, Bruxelles (BE)  
**D. Isenberg**, London (UK)  
**J. Kalden**, Erlangen (DE)  
**C. Kallenberg**, Amsterdam (NL)  
**M. Khamashta**, London (UK)  
**H.M. Moutsopoulos**, Athens (GR)  
**L. Rönnblom**, Uppsala (SE)  
**M. Schneider**, Düsseldorf (DE)  
**J. Smolen**, Vienna (AT)  
**E. Svenungsson**, Stockholm (SE)  
**A. Tincani**, Brescia (IT)  
**C. Vasconcelos**, Porto (PT)



## PRELIMINARY FACULTY LIST

**Marta Alarcón Riquelme** | Spain  
**José Alves** | Portugal  
**Jeanette Andersen** | Denmark  
**Simone Appenzeller** | Brazil  
**Martin Aringer** | Germany  
**Laurent Arnaud** | France  
**René Bernard** | Germany  
**Miguel Bernardes** | Portugal  
**Maria Laura Bertolaccini** | United Kingdom  
**George Bertsias** | Greece  
**Dimitrios Boumpas** | Greece  
**Ian N. Bruce** | Ireland  
**Ricard Cervera** | Spain  
**Howard Y. Chang** | USA  
**Fabrizio Conti** | Italy  
**Patrícia Costa Reis** | Portugal  
**Nathalie Costedoat-Chalumeau** | France  
**Luís Cunha Miranda** | Portugal  
**Andrea Doria** | Italy  
**Thomas Dörner** | Germany  
**Antonios Fanouriakis** | Greece  
**Raquel Faria** | Portugal  
**Francesca Faustini** | Sweden  
**Andrea Fava** | USA  
**Rebecca Fischer-Betz** | Germany  
**Richard Furie** | USA  
**Maria Galindo Izquierdo** | Spain  
**Mariele Gatto** | Italy  
**Margarida Gonçalo** | Portugal  
**Luís Graça** | Portugal  
**Frédéric Houssiau** | Belgium  
**Luca Iaccarino** | Italy  
**Luís Inês** | Portugal  
**David Isenberg** | United Kingdom  
**Diogo Jesus** | Portugal  
**Zoe Karakikla-Mitsakou** | Belgium  
**Karoline Lerang** | Norway  
**Francesca Marchiori** | Italy

**António Marinho** | Portugal  
**Branka Marinovic** | Croatia  
**Chi Chiu Mok** | Hong Kong  
**Eric Morand** | Australia  
**Marta Mosca** | Italy  
**Paulo Oliveira** | Portugal  
**Ioannis Parodis** | Sweden  
**Bernardo Pons-Estel** | Argentina  
**Guillermo Pons-Estel** | Argentina  
**Anisur Rahman** | United Kingdom  
**Sofia Ribeiro** | Portugal  
**Gilberto Rosa** | Portugal  
**Brad Rovin** | USA  
**Lars Rönnblom** | Sweden  
**Maria José Santos** | Portugal  
**Matthias Scheneider** | Germany  
**Georg Schett** | Germany  
**Jonathan Schiött** | Sweden  
**Savino Sciascia** | Italy  
**Yehuda Shoenfeld** | Israel  
**Cristiana Sieiro Santos** | United Kingdom  
**Clovis Silva** | Brazil  
**Annemarie Sluijmers** | Belgium  
**Elisabet Svenungsson** | Sweden  
**Maria G. Tektonidou** | Greece  
**Yoe Kie Onno Teng** | The Netherlands  
**Angela Tincani** | Italy  
**Zahi Touma** | Canada  
**Anne Troldborg** | Denmark  
**George C. Tsokos** | USA  
**Manuel Ugarte-Gil** | Peru  
**Ronald F. van Vollenhoven** | The Netherlands  
**Carlos Vasconcelos** | Portugal  
**Vincenzo Venerito** | Italy  
**Edward Vital** | United Kingdom  
**Tracey Weissgerber** | Portugal  
**Victoria Werth** | USA  
**Chris Wincup** | United Kingdom



## PROGRAMME OVERVIEW

### WEDNESDAY, 4 MARCH 2026

hrs	Auditorium I	Auditorium II
09:00	Registration Opening	
09:00-11:00		Pre-meeting course: European Forum on Antiphospholipid Antibodies Scientific Session 1
11:00-11:30		Coffee break
11:30-13:00		Pre-meeting course: European Forum on Antiphospholipid Antibodies Scientific Session 2
13:00-14:00		Lunch and Poster discussion
14:00-16:30		Pre-meeting course: European Forum on Antiphospholipid Antibodies Scientific Session 3
17:00-17:30	Welcome to Lupus 2026	
17:30-18:00	Keynote Lecture 1	
18:00-18:30	Keynote Lecture 2	
18:30-21:30	Opening Ceremony	

### THURSDAY, 5 MARCH 2026

hrs	Auditorium I	Auditorium II	Auditorium III	Auditorium IV	Meeting Room 1.09	Fishbowls Area 1	Fishbowls Area 2	Fishbowls Area 3	Fishbowls Area 4
08:00-08:30		Industry Sponsored Symposium							
08:30-10:00	Session 1 Cutaneous lupus	Session 2 Digital health							
10:00-10:30		Coffee break							
10:30-12:00	Session 3 Neuropsychiatric lupus	Session 4 Pathogenesis							
12:00-13:00	Industry Sponsored Symposium	Industry Sponsored Symposium	Industry Sponsored Symposium						
13:00-14:30		Lunch and Short Oral Presentations NO CME Sessions at 13:45-14:30 in Rooms 1.05-1.06-1.07-1.08			Young SLEuro Forum NO CME 13:30-14:15				
14:30-15:30	Session 5 Debate: Do we have disease-modifying drugs for SLE?	Session 6 Genetics							
15:30-16:15			Interactive Workshop 1 The Skin in Lupus: mimics and red flags	Interactive Workshop 2 Lupus Unplugged: a candid Q&A between patients and physicians		Fishbowl Lupus Clinical trials: which outcomes best define success?	Fishbowl How can AI transform lupus care and research?	Fishbowl Finding the right dose: HCQ in Lupus	Fishbowl Multicentre cohorts in lupus: how do we collaborate effectively?
16:15-16:45		Coffee break							
16:45-18:15	Session 7 Treat-to-target in SLE	Session 8 Antiphospholipid syndrome							
18:15-19:15	Industry Sponsored Symposium		Industry Sponsored Symposium						



PROGRAMME OVERVIEW

**FRIDAY, 6 MARCH 2026**

hrs	Auditorium I	Auditorium II	Auditorium III	Auditorium IV	Meeting Room 1.09	Fishbowls Area 1	Fishbowls Area 2	Fishbowls Area 3	Fishbowls Area 4
08:00-09:00			SLEuro General Assembly						
09:00-10:30	Session 9 Lupus nephritis	Session 10 Biomarkers							
10:30-11:00		Coffee break							
11:00-12:00	Session 11 Debate: When are biologics best used in SLE?	Session 12 Epidemiology of SLE							
12:00-13:00	Industry Sponsored Symposium	Industry Sponsored Symposium		Industry Sponsored Symposium		Industry Sponsored Symposium Pro-Con Innovative Talk			
13:00-14:30			Lunch and Short Oral Presentations NO CME Sessions at 13:45-14:30 in Rooms 1.05-1.06-1.07-1.08						
14:30-15:30	Industry Sponsored Symposium	Industry Sponsored Symposium							
15:30-16:15			Interactive Workshop 3 Transition of lupus patients from pediatric to adult health care	Interactive Workshop 4 ReproducibiliTeach: Using reporting guidelines and author contributions statements to improve the transparency and reproducibility of your research		Fishbowl Lupus and infection risk: how can we protect patients?	Fishbowl How do we optimize treat-to-target of lupus nephritis?	Fishbowl Young clinicians in Lupus: how to build a successful career Path?	Fishbowl Glucocorticoids in lupus: when and how to stop?
16:15-16:45		Coffee break							
16:45-18:15	Session 13 Outcome measures in SLE	Session 14 Lupus nephritis: translational insights							
18:15-19:15				Industry Sponsored Symposium					

**SATURDAY, 7 MARCH 2026**

hrs	Auditorium I	Auditorium II	Auditorium III	Auditorium IV	Meeting Room 1.09	Fishbowls Area 1	Fishbowls Area 2	Fishbowls Area 3	Fishbowls Area 4
08:00-09:00									
09:00-10:30	Session 15 Novel therapies and treatment strategies for SLE	Session 16 Optimising patient care							
10:30-11:00		Coffee break							
11:00-11:45			Interactive Workshop 5 Women's health and pregnancy in SLE and APS	Interactive Workshop 6 Keep it in mind! - Interactive Clinical Case discussion		Fishbowl Early diagnosis of lupus: how can we improve?	Fishbowl How can we better prevent lupus flares?	Fishbowl Biologics and cell therapies in SLE: Who truly benefit?	Fishbowl Managing non-inflammatory manifestations in Lupus: how can we do better?
11:45-12:30	Plenary Session Highlights								
12:30-12:45	Closing Ceremony								



## SCIENTIFIC PROGRAMME

### WEDNESDAY, 4 MARCH 2026

#### APL FORUM PRE-MEETING COURSE: EUROPEAN FORUM ON ANTIPHOSPHOLIPID ANTIBODIES

##### Auditorium II

09:00-11:00	Scientific session 1
11:00-11:30	Coffee break
11:30-13:00	Scientific session 2
13:00-14:00	Lunch and Poster discussion
14:00-16:30	Scientific session 3

### OPENING SESSION

##### Auditorium I

17:00-17:30	<b>WELCOME TO LUPUS 2026</b> <b>L. Inês</b> (Coimbra, Portugal), <b>M.J. Santos</b> (Almada, Portugal), <b>J. Andersen</b> (Copenhagen, Denmark)
17:30-18:00	<b>Keynote Lecture I - New perspectives on the management of SLE: Lessons from the Padua Lupus Cohort</b> <b>A. Doria</b> (Padua, Italy)
18:00-18:30	<b>Keynote Lecture II - Addressing Health Inequalities in SLE: a Global Challenge</b> <b>I.N. Bruce</b> (Manchester, UK)
18:30-21:30	<b>OPENING CEREMONY</b>



## THURSDAY, 5 MARCH 2026

### Auditorium II

08:00-08:30 INDUSTRY – SPONSORED SYMPOSIUM

### Auditorium III+IV

08:00-08:30 INDUSTRY – SPONSORED SYMPOSIUM

### Meeting Room 1.07

08:00-08:30 INDUSTRY – SPONSORED SYMPOSIUM

### 08:30-10:00 SESSION 1 - CUTANEOUS LUPUS

#### Auditorium I

**Chairs** K. Lerang (Oslo, Norway), A. Marinho (Braga, Portugal),  
A. Sluijmers (Bruxelles, Belgium)

08:30-08:55 **Diagnosis and management recommendations of cutaneous lupus**  
**B. Marinovic** (Zagreb, Croatia)

08:55-09:20 **Pathogenesis insights for new treatments of cutaneous lupus**  
**M. Gonçalo** (Coimbra, Portugal)

09:20-09:45 **Critical appraisal of outcome measures for cutaneous lupus**  
**V. Werth** (Philadelphia, USA)

09:45-09:59 **Oral communications**

09:59-10:00 **Closing remarks**

### 08:30-10:00 SESSION 2 - DIGITAL HEALTH

#### Auditorium II

**Chairs** L. Cunha Miranda (Lisbon, Portugal), Z. Karakikla-Mitsakou (Bruxelles, Belgium),  
O. Teng (Leiden, Netherlands)

08:30-08:55 **The digital lupus patient pathway**  
**L. Arnaud** (Strasbourg, France)

08:55-09:20 **Virtual Patient Simulations Using Social Robotics for Clinical Reasoning Training**  
**J. Schiött** (Stockholm, Sweden)

09:20-09:45 **Advancements of Artificial Intelligence in SLE Research**  
**V. Venerito** (Bari, Italy)

09:45-09:59 **Oral communications**

09:59-10:00 **Closing remarks**

10:00-10:30 **Coffee break**



10:30-12:00 **SESSION 3 - NEUROPSYCHIATRIC LUPUS**

**Auditorium I**

**Chairs** M. Bernardes (Coimbra, Portugal), C.C. Mok (Hong Kong, China),  
S. Ribeiro (Lisbon, Portugal)

10:30-10:55 **Neuropsychiatric lupus: an enigma wrapped up in a therapeutic puzzle**  
**D. Isenberg** (London, UK)

10:55-11:20 **Cognitive function in patients with SLE**  
**Z. Touma** (Toronto, Canada)

11:20-11:45 **The role of neuroimaging in SLE**  
**S. Appenzeller** (São Paulo, Brazil)

11:45-11:59 **Oral communications**

11:59-12:00 **Closing remarks**

10:30-12:00 **SESSION 4 - PATHOGENESIS**

**Auditorium II**

**Chairs** L. Graça (Lisbon, Portugal), L. Rönnblom (Uppsala, Sweden)

10:30-10:55 **Immunometabolism in SLE T cells**  
**G. Tsokos** (Boston, USA)

10:55-11:20 **Translational Insights Transforming B Cell Targeting in SLE**  
**T. Dörner** (Berlin, Germany)

11:20-11:45 **Targeting Mitochondria in SLE**  
**P. Oliveira** (Coimbra, Portugal)

11:45-11:59 **Oral communications**

11:59-12:00 **Closing remarks**



**Auditorium I**

12:00-13:00 **INDUSTRY – SPONSORED SYMPOSIUM**

**Auditorium II**

12:00-13:00 **INDUSTRY – SPONSORED SYMPOSIUM**

**Auditorium III+IV**

12:00-13:00 **INDUSTRY – SPONSORED SYMPOSIUM**

**Meeting Room 1.07**

12:00-13:00 **INDUSTRY – SPONSORED SYMPOSIUM**

13:00-14:30 **Lunch & Poster Tour**

**14:30-15:30 SESSION 5 - DEBATE: DO WE HAVE DISEASE-MODIFYING DRUGS FOR SLE?**

**Auditorium I**

**Chairs** L. Arnaud (Strasbourg, France), M. Mosca (Pisa, Italy)

**14:30-15:00 Yes**  
M. Ugarte-Gil (Lima, Peru)

**15:00-15:30 No**  
A. Fanouriakis (Athens, Greece)

**14:30-15:30 SESSION 6 - GENETICS**

**Auditorium II**

**Chairs** P. Costa Reis (Lisbon, Portugal), G. Tsokos (Boston, USA)

**14:30-14:50 Consequences of harboring SLE risk genes**  
L. Rönnblom (Uppsala, Sweden)

**14:50-15:10 The role of genetics in B cell homeostasis in SLE**  
M. Alarcón Riquelme (Granada, Spain)

**15:10-15:30 Genetic drivers of female sex-biased autoimmunity**  
H.Y. Chang (Stanford, USA)



## INTERACTIVE WORKSHOPS

### Auditorium III

15:30-16:15 **Interactive Workshop 1 – The Skin in Lupus: mimics and red flags**

**M. Gonçalo** (Coimbra, Portugal), **B. Marinovic** (Zagreb, Croatia),  
**G. Rosa** (Porto, Portugal)

### Auditorium IV

15:30-16:15 **Interactive Workshop 2 - Lupus Unplugged:**

**a candid Q&A between patients and physicians (SLEuro & Lupus Europe)**  
**M. Gatto** (Turin, Italy), **C. Sieiro Santos** (Manchester, UK) & 2 patients

## FISHBOWLS

### Fishbowl Area 1

15:30-16:15 **Fishbowl Discussion**

### Fishbowl Area 2

15:30-16:15 **Fishbowl Discussion**

### Fishbowl Area 3

15:30-16:15 **Fishbowl Discussion**

16:15-16:45 **Coffee break**

## 16:45-18:15 SESSION 7 - TREAT-TO-TARGET IN SLE

### Auditorium I

**Chairs** **G. Bertsias** (Crete, Greece), **F. Marchiori** (Rome, Italy), **E. Morand** (Boston, USA)

16:45-17:10 **The preclinical phase of autoimmunity: could SLE be prevented?**  
**E. Vital** (Leeds, UK)

17:10-17:35 **Targets for treating SLE: low disease activity, remission, or deep and lasting remission?**  
**R. van Vollenhoven** (Amsterdam, Netherlands)

17:35-18:00 **Is Treat to Target achieved commonly in patients with SLE?**  
**A. Rahman** (London, UK)

18:00-18:14 **Oral communications**

18:14-18:15 **Closing remarks**



16:45-18:15 **SESSION 8 - ANTIPHOSPHOLIPID SYNDROME**

**Auditorium II**

**Chairs** J. Alves (Lisbon, Portugal), N. Costedoat-Chalumeau (Paris, France)

16:45-17:10 **Classification and diagnosis of APS in practice**  
S. Sciascia (Turin, Italy)

17:10-17:35 **How to measure disease activity in APS?**  
M. Tektonidou (Athens, Greece)

17:35-18:00 **How to assess damage in APS?**  
M.L. Bertolaccini (London, UK)

18:00-18:14 **Oral communications**

18:14-18:15 **Closing remarks**

**Auditorium II**

18:15-19:15 **INDUSTRY – SPONSORED SYMPOSIUM**

**Auditorium III+IV**

18:15-19:15 **INDUSTRY – SPONSORED SYMPOSIUM**

**Meeting Room 1.07**

18:15-19:15 **INDUSTRY – SPONSORED SYMPOSIUM**



## FRIDAY, 6 MARCH 2026

### SLEURO GENERAL ASSEMBLY

Auditorium II

08:00-09:00 SLEURO GENERAL ASSEMBLY

### 09:00-10:30 SESSION 9 - LUPUS NEPHRITIS

Auditorium I

**Chairs** D. Boumpas (Athens, Greece), B. Rovin (Columbus, USA)

09:00-09:25 **B-cell therapies for lupus nephritis: What is new?**  
R. Furie (New York, USA)

09:25-09:50 **Treatment of LN from a nephrology perspective**  
O. Teng (Leiden, Netherlands)

09:50-10:15 **Will targeted therapies change the landscape of lupus nephritis?**  
F. Houssiau (Bruxelles, Belgium)

10:15-10:29 **Oral communications**

10:29-10:30 **Closing remarks**

### 09:00-10:30 SESSION 10 - BIOMARKERS

Auditorium II

**Chairs** T. Dörner (Berlin, Germany), Y. Shoenfeld (Tel Aviv, Israel)

09:00-09:25 **Autoantibody defined subgroups in SLE**  
E. Svenungsson (Stockholm, Sweden)

09:25-09:50 **Advanced proteomics for discovery in SLE**  
A. Troldborg (Aarhus, Denmark)

09:50-10:15 **Biological aspects associated with type I interferon pathway in SLE**  
G. Bertsias (Crete, Greece)

10:15-10:29 **Oral communications**

10:29-10:30 **Closing remarks**

10:30-11:00 **Coffee break**



11:00-12:00 **SESSION 11 - DEBATE: WHEN ARE BIOLOGICS BEST USED IN SLE?**

**Auditorium I**

**Chairs** M. Tektonidou (Athens, Greece), R. van Vollenhoven (Amsterdam, The Netherlands)

11:00-11:30 **First-line immunosuppression**

**M. Gatto** (Turin, Italy)

11:30-12:00 **For refractory disease**

**C. Wincup** (London, UK)

11:00-12:00 **SESSION 12 - EPIDEMIOLOGY OF SLE**

**Auditorium II**

**Chairs** F. Faustini (Stockholm, Sweden), F. Marchiori (Rome, Italy),  
C. Vasconcelos (Porto, Portugal)

11:00-11:20 **EULAR/ACR Classification Criteria in their 7th year – Learnings  
and implications for SLE as a disease entity**

**M. Aringer** (Dresden, Germany)

11:20-11:40 **Incidence and prevalence of SLE worldwide**

**K. Lerang** (Oslo, Norway)

11:40-12:00 **Lessons from the GLADEL registry**

**B. Pons-Estel** (Rosario, Argentina)

**Auditorium I**

12:00-13:00 **INDUSTRY – SPONSORED SYMPOSIUM**

**Auditorium II**

12:00-13:00 **INDUSTRY – SPONSORED SYMPOSIUM**

**Auditorium III+IV**

12:00-13:00 **INDUSTRY – SPONSORED SYMPOSIUM**

**Meeting Room 1.07**

12:00-13:00 **INDUSTRY – SPONSORED SYMPOSIUM**

13:00-14:30 **Lunch & Poster Tour**



## Auditorium I

14:30-15:30 **INDUSTRY – SPONSORED SYMPOSIUM**

## Auditorium II

14:30-15:30 **INDUSTRY – SPONSORED SYMPOSIUM**

## INTERACTIVE WORKSHOPS

### Auditorium III

15:30-16:15 **Interactive Workshop 3 – Transition of lupus patients from pediatric to adult health care**  
P. Costa Reis (Lisbon, Portugal), C. Silva (São Paulo, Brazil)

### Auditorium IV

15:30-16:15 **Interactive Workshop 4 – ReproducibiliTeach: Using reporting guidelines and author contributions statements to improve the transparency and reproducibility of your research**  
R. Bernard (Berlin, Germany), T. Weissgerber (Coimbra, Portugal)

## FISHBOWLS

### Fishbowl Area 1

15:30-16:15 **Fishbowl Discussion**

### Fishbowl Area 2

15:30-16:15 **Fishbowl Discussion**

### Fishbowl Area 3

15:30-16:15 **Fishbowl Discussion**

16:15-16:45 **Coffee break**



16:45-18:15

## SESSION 13 - OUTCOME MEASURES IN SLE

Auditorium I

**Chairs** J. Andersen (Copenhagen, Denmark), I.N. Bruce (Manchester, UK), A. Doria (Padua, Italy)

16:45-17:10 **New outcome measures for SLE clinical trials**  
**E. Morand** (Melbourne, Australia)

17:10-17:35 **Can we harmonize SLE disease activity assessment across clinical practice and clinical trials?**  
**D. Jesus** (Leiria, Portugal)

17:35-18:00 **Assessing damage in SLE**  
**M. Galindo Izquierdo** (Madrid, Spain)

18:00-18:14 **Oral communications**

18:14-18:15 **Closing remarks**

16:45-18:15

## SESSION 14 - LUPUS NEPHRITIS: TRANSLATIONAL INSIGHTS

Auditorium II

**Chairs** R. Furie (New York, USA), M. Gatto (Turin, Italy)

16:45-17:10 **The kidney biopsy in lupus nephritis: beyond routine histology**  
**B. Rovin** (Columbus, USA)

17:10-17:35 **Molecular characterisation to guide diagnosis and therapy in lupus nephritis**  
**I. Parodis** (Stockholm, Sweden)

17:35-18:00 **Urinary biomarkers in lupus nephritis**  
**A. Fava** (Baltimore, USA)

18:00-18:14 **Oral communications**

18:14-18:15 **Closing remarks**

Auditorium II

18:15-19:15 **INDUSTRY – SPONSORED SYMPOSIUM**

Auditorium III+IV

18:15-19:15 **INDUSTRY – SPONSORED SYMPOSIUM**

Meeting Room 1.07

18:15-19:15 **INDUSTRY – SPONSORED SYMPOSIUM**



## SATURDAY, 7 MARCH 2026

### Auditorium II

08:00-09:00 INDUSTRY – SPONSORED SYMPOSIUM

### Auditorium III+IV

08:00-09:00 INDUSTRY – SPONSORED SYMPOSIUM

### Meeting Room 1.07

08:00-09:00 INDUSTRY – SPONSORED SYMPOSIUM

## 09:00-10:30 SESSION 15 – NOVEL THERAPIES AND TREATMENT STRATEGIES FOR SLE

### Auditorium I

**Chairs** A. Troldborg (Aarhus, Denmark), E. Vital (Leeds, UK)

09:00-09:25 **CAR-T and other cell therapies in SLE**  
G. Schett (Erlangen, Germany)

09:25-09:50 **Novel targeted small molecules in SLE**  
C.C. Mok (Hong Kong, China)

09:50-10:15 **Evidence-based strategy for use of biologics in SLE**  
R. Cervera (Barcelona, Spain)

10:15-10:29 **Oral communications**

10:29-10:30 **Closing remarks**

## 09:00-10:30 SESSION 16 – OPTIMISING PATIENT CARE

### Auditorium II

**Chairs** J. Andersen (Copenhagen, Denmark), F. Conti (Rome, Italy),  
G. Pons-Estel (Rosario, Argentina)

09:00-09:25 **What makes lupus difficult to treat?**  
M. Mosca (Pisa, Italy)

09:25-09:50 **How to enhance adherence to treatment**  
N. Costedoat-Chalumeau (Paris, France)

09:50-10:15 **Shared decision making – what are the risks and options in SLE?**  
M. Schneider (Düsseldorf, Germany)

10:15-10:29 **Oral communications**

10:29-10:30 **Closing remarks**

10:30-11:00 **Coffee break**



## INTERACTIVE WORKSHOPS

### Auditorium III

11:00-11:45 **Interactive workshop 5 - Women's health and pregnancy in SLE and APS**  
**A. Tincani** (Brescia, Italy), **R. Fischer-Betz** (Düsseldorf, Germany)

### Auditorium IV

11:00-11:45 **Interactive workshop 6 - Keep it in mind! - Interactive Clinical Case discussion**  
**R. Faria** (Porto, Portugal), **F. Faustini** (Stockholm, Sweden),  
**L. Iaccarino** (Padua, Italy)

## FISHBOWLS

### Fishbowl Area 1

11:00-11:45 **Fishbowl Discussion**

### Fishbowl Area 2

11:00-11:45 **Fishbowl Discussion**

### Fishbowl Area 3

11:00-11:45 **Fishbowl Discussion**

## 11:45-12:30 PLENARY SESSION – HIGHLIGHTS

### Auditorium I

11:45-12:05 **Translational**  
**I. Parodis** (Stockholm, Sweden)

12:05-12:25 **Clinical**  
**Z. Touma** (Toronto, Canada)

12:25-12:30 **Closing remarks**

## CLOSING SESSION

### Auditorium I

12:30-12:45 **CLOSING CEREMONY**  
**L. Inês** (Coimbra, Portugal), **M.J. Santos** (Lisbon, Portugal),  
**J. Andersen** (Copenhagen, Denmark), **I. Parodís** (Stockholm, Sweden)



## SCIENTIFIC INFORMATION

### IMPORTANT DATES

Abstract submission deadline	<b>20 October 2025</b>
Abstract notification	<b>1 December 2025</b>
Late-breaking abstract submission opening	<b>15 December 2025</b>
Late-breaking abstract submission deadline	<b>15 January 2026</b>
Early registration deadline	<b>8 December 2025</b>
Regular registration deadline	<b>15 February 2026</b>

### 13<sup>TH</sup> EUROPEAN FORUM ON ANTI PHOSPHOLIPID ANTIBODIES

The APL Forum will be organized on 4 March, from 09:00 to 16:30, in the Auditorium II. The programme will focus on different aspects of physiopathology, from oxidation to immune activation and coagulopathy, looking into the different clinical phenotypes and at existing treatment perspectives, as well as the new therapeutic approaches that are being lined up for the years to come.

Registration for the APL Forum Pre-Meeting Course is free on condition that registration for the congress is confirmed. Participation is subject to limited availability.

### FISHBOWL DISCUSSIONS

Nine interactive sessions, known as "Fishbowls", will be held throughout the meeting in three different areas of the congress venue. All delegates will be invited to choose and attend the session that best matches their area of interest.

#### What is a Fishbowl?

The fishbowl is a dynamic and participatory discussion format designed to facilitate meaningful group conversations. Rather than involving the entire audience at once, a small group of 3 to 6 participants sits in an inner circle to discuss a specific topic, while the rest of the attendees form an outer circle to observe.



A key feature of the fishbowl is the empty chair in the inner circle, which allows a member of the audience to join the discussion temporarily. This encourages active engagement from all participants. A moderator briefly introduces the topic and then steps back, intervening only when necessary to guide the discussion or ensure that rules are followed.

### Fishbowls at a glance

- Discussion takes place in the inner circle
- Observers sit in the outer circle, reflecting and listening
- The empty chair allows spontaneous contributions from the audience
- A moderator introduces the topic and ensures smooth flow
- A recorder captures key points and outcomes

### Basic Rules

- 4 participants + 1 empty chair in the inner circle
- Only members of the inner circle may speak
- One speaker at a time
- Each contribution should relate to the previous one
- The empty chair allows audience members to join the discussion by asking a question or sharing an opinion
- After speaking, the guest participant returns to the outer circle
- The audience observes, takes notes, and can participate through the empty chair
- The moderator introduces the topic, ensures adherence to the rules, and only intervenes when necessary

## INTERACTIVE WORKSHOPS

Six interactive workshops will be held during the congress in Auditorium III and IV, covering a variety of practical and patient-centered topics, including cutaneous lupus, candid conversations between patients and physicians, pediatric SLE and transition, research reproducibility, women's health and pregnancy in SLE/APS, and challenging clinical cases discussions. Participation is subject to seat availability.

## ABSTRACTS

The deadline for the abstract submission is **20 October 2025**.

After the deadline, the Scientific Committee will review all submitted abstracts and allocate them to the appropriate sessions as either oral presentations or e-posters.

Notification of acceptance or rejection will be sent to the corresponding author **by 1 December 2025**.



A late-breaking submission will be open from 15 December 2025 to 15 January 2026.

The presenting author of an accepted abstract must register for the Congress.

For more information on abstract submission and guidelines, please click [here](#).

## ORAL COMMUNICATIONS

All abstracts accepted as oral communications will be scheduled in dedicated scientific sessions.

Presenters will have 5 minutes for their presentation followed by 2 minutes for discussion.

Further information will be sent to the authors of the accepted abstracts.

## POSTERS

All abstracts accepted as posters will be printed and displayed in the poster area in Pavilion 4. Presenters will be asked to stand by their posters during the assigned time slots to answer any questions from participants.

Poster tours will also be organized during the designated lunch break sessions on **Thursday 5 and Friday 6 March, from 13:45 to 14:30**, as indicated in the programme. More detailed information will follow.

All presentations, discussions, and Q&A must be conducted in English.

## ABSTRACT BOOK

All abstracts accepted as oral presentations or posters will be included in an Abstract Book, which will be officially issued in the journal **Lupus Science & Medicine** a few days prior to the start of the Congress.

The Abstract Book will be made available exclusively in electronic format and accessible for download on the official congress website.

Please note that the presenting author of each accepted abstract must complete registration by the end of January 2026 and attend the Congress; failure to do so will result in the withdrawal of the abstract from the Abstract Book.

**LUPUS**  
SCIENCE &  
MEDICINE®



## CME CREDITS

An application will be submitted to the EACCME® for CME accreditation of this event.

## CME PROVIDER



### AIM Education – Provider n. 93

Viale E. Forlanini, 23 - 20134 Milan, Italy  
Tel. +39 02 566011  
[cme@aimgroup.eu](mailto:cme@aimgroup.eu)  
[www.aimeducation.it](http://www.aimeducation.it)

## SCIENTIFIC SECRETARIAT



**AIM Group International - Milan Office**  
Viale E. Forlanini, 23 - 20134 Milan, Italy  
Ph. +39 02 566011  
[sleurosecretariat@aimgroup.eu](mailto:sleurosecretariat@aimgroup.eu)  
[www.sleuro.org](http://www.sleuro.org)

## ORGANIZING SECRETARIAT



**AIM Group International - Milan Office**  
Viale E. Forlanini, 23 - 20134 Milan, Italy  
Ph. +39 02 566011  
[lupus2026@aimgroup.eu](mailto:lupus2026@aimgroup.eu)  
[www.sleuromeeting.eu](http://www.sleuromeeting.eu)



## GENERAL INFORMATION

### CONGRESS VENUE

#### Lisbon Congress Centre (CCL)

Praça das Indústrias 1,  
1300-307 Lisboa  
Portugal





## HOW TO REACH THE VENUE

### By flight

The Humberto Delgado Airport is located 12 km (approximately 15/20 minutes by car) from the Lisbon Congress Centre (CCL), providing flights to more than 125 national and international destinations.

Taxis are readily available outside the airport terminal. The fare should be around €10-€15. Ride-sharing services such as Uber and Bolt are also good alternatives.

Moreover, there are several bus and tram options available to reach the venue. For the most convenient route, please consult Google Maps.

### By train

The Gare do Oriente station is the main railway hub in scenic Lisbon and one of the most spectacular train stations in Portugal and in Europe. The station serves dozens of domestic and international routes and welcomes more than 75 million travelers every year.

The station is located 14 km from the congress venue (about 24 minutes by car).

There are several bus and tram options available to reach the venue. For the most convenient route, please consult Google Maps.

### By car

The CCL is accessible via Portugal's main national road accesses, the A5, A2 and the Ponte 25 de Abril (The April 25<sup>th</sup> Bridge).

### Parking lots

Next to the CCL, there are two parking lots with a total of 1,100 spaces. These are paid facilities and are not directly managed by the venue.



## ACCOMMODATION

The Organizing Secretariat has reserved a block of rooms in various hotels near the congress venue or close to public transportation hubs, across different categories. The hotel list is available [here](#).

We highly recommend taking advantage of this opportunity and booking your accommodation as early as possible.

For reservations, please contact:



### AIM Portugal

Avenida Conde de Valbom 6 - 1050-068 Lisbon, Portugal

Ph. +351 21 324 5040

[lupus2026.hotel@aimgroup.eu](mailto:lupus2026.hotel@aimgroup.eu)

## SECRETARIAT AND REGISTRATION DESK

The on-site registration desks will be open during the following days:

Wednesday, 4 March 2026	<b>09.00 - 18.30</b>
Thursday, 5 March 2026	<b>07.30 - 19.15</b>
Friday, 6 March 2026	<b>07.30 - 18.15</b>
Saturday, 7 March 2026	<b>07.30 - 13.00</b>

## ACCESS

All participants will receive instructions for self-registration and printing their badge upon arrival at the venue.

Wearing the badge is mandatory at all times during congress activities.

The badge grants access to all scientific sessions, the exhibition area, coffee breaks, and lunches.

Please note that in case of loss, a reprint fee will be charged for issuing a new badge.

## OPENING LECTURE

The Opening Lecture, held by the Congress Chairs, Prof. Luís Inês and Prof. Maria José Santos, along with Lupus Europe's CEO, Jeanette Andersen, will be held on 4 March, at 17:00.



## OPENING CEREMONY AND WELCOME COCKTAIL

The Opening Ceremony of the Congress will be held at the end of the congress lectures on 4 March at 18.30. A standing buffet dinner will follow.

## APP

The official Congress App will be soon available on all the stores. All participants equipped with a tablet or smartphone running iOS or Android will be able to download the app free of charge, gaining access to all real-time updates and congress information.

In addition to browsing the scientific programme and general information, the app will offer the following features:

- **Q&A** – Join the conversation during sessions by submitting your questions through the session chat
- **Venue and Exhibition Area Map** – Easily find your way around the venue
- **Agenda** – Create your own personalised agenda by selecting the sessions you wish to attend. You will receive a notification whenever one of your selected sessions is about to begin.

## LANGUAGE

The official language is English. No simultaneous translation will be provided.

## ATTENDANCE CERTIFICATES

Participants will be able to download and print the certificate of attendance upon completion of the online evaluation form through a dedicated platform. The instructions will be sent by e-mail after the Congress.

## VISA REQUIREMENTS

All non-Portuguese nationals entering Portugal must provide valid travel documentation. Delegates who hold neither an EU passport nor a Schengen visa should check as soon as possible the Portuguese Ministry of Foreign Affairs' website to see if they require a visa to enter the country. Visa regulations depend on your nationality and country of origin. For the most updated information regarding visa requirements, we do suggest you contact your local consulate for full and official instructions on the specific visa regulations and application procedures that apply to you.

If a visa is required, delegates should apply to the Portuguese Diplomatic and Consular Representations in their country of residence with the documents outlined on the Ministry of Foreign Affairs' website. Invitation letters to the conference may be downloaded online through the registration area of our website.



Please Note: Visa applications may take several months. Therefore, we recommend checking all the necessary requirements and procedures well ahead of time.

Visa application fees vary. Please contact the embassy or consulate to enquire about costs.

Presentation of the requested documentation does not guarantee that the visa will be issued.

AIM Group International will be glad to assist you if you need any other written invitation or other document to support your visa application at the following e-mail address: [visa@aimgroup.eu](mailto:visa@aimgroup.eu)

### **Invitation letter**

The official invitation letter to be included in your application to enter Portugal can be downloaded through the registration page. [Click here](#)

If you have not submitted your personal data yet, click on "First time user" and fill in the form with your personal data. Once you have completed the form, click on "Invitation Letter(VISA)" on the left side menu.

If you have already submitted your personal data, just log in (using your User ID and Password) and click on "Edit your personal data" to insert the passport details. Then, click on "Invitation Letter(VISA)" from the left side menu.

The Invitation Letter will not be legally or financially binding on the organizing secretariat. Expenses related to the conference shall be borne by delegates themselves.

### **EXHIBITION**

An exhibition of pharmaceutical and technical products will take place in the Congress Venue throughout the Meeting. Additional opportunities for sponsorship are available. To receive the Sponsor Prospectus please contact the Organizing Secretariat:

### **ORGANIZING SECRETARIAT**



#### **AIM Group International - Milan Office**

Viale E. Forlanini, 23 - 20134 Milan, Italy

Ph. +39 02 566011

[lupus2026@aimgroup.eu](mailto:lupus2026@aimgroup.eu)

[lupus2026.sponsor@aimgroup.eu](mailto:lupus2026.sponsor@aimgroup.eu)

[www.sleuromeeting.eu](http://www.sleuromeeting.eu)



## REGISTRATIONS

All fees are 23% VAT included.

Category	Early Bird Fee until 8 December 2025	Regular Fee until 15 February 2026	Late and on-site Fee from 15 February 2026
SLEuro Member	<b>€ 575,00</b>	<b>€ 625,00</b>	<b>€ 675,00</b>
Non-Member	<b>€ 625,00</b>	<b>€ 675,00</b>	<b>€ 725,00</b>
Student/Trainee*	<b>€ 325,00</b>	<b>€ 325,00</b>	<b>€ 375,00</b>
Health Professional Non-MD/Researcher**	<b>€ 325,00</b>	<b>€ 325,00</b>	<b>€ 375,00</b>
Low & Lower-middle-income economies SLEuro Member ***	<b>€ 200,00</b>		
Low & Lower-middle-income economies Non-Member ***	<b>€ 250,00</b>		
Patient - Full Period****	<b>€ 100,00</b>		<b>€ 150,00</b>
Patient - 1 Day****	<b>€ 50,00</b>		<b>€ 50,00</b>
APL Forum*****	<b>Free</b>		

\* In order to benefit from the special fee, a submission of your status confirmation (approval letter signed by the Head of Department or copy of your status ID) must be uploaded during registration procedure.

\*\* Nurses, physiotherapists, occupational therapists and other nearby allied health professionals. A letter of confirmation of your status from the Head of Unit or Institute must be uploaded during registration procedure.

\*\*\* Lower and Middle Country classification as listed and defined according to the [World Bank website](#).

\*\*\*\* Patients registering at this fee must upload a proof of their status declaration from a doctor or a proof of their membership in a Patient Association during the registration process. If no certificate is being uploaded, the registration process cannot be completed. Please note that you might not have access to industry sponsored satellite symposia and exhibition area.

\*\*\*\*\* Registration for the APL Forum Pre-Meeting Course is free on condition that registration for the congress is confirmed. The participation is subject to limited availability.

The delegate fee includes:

- Admission to the scientific sessions
- Welcome cocktail on Wednesday 4 March
- Certificate of attendance
- Access to the exhibition and e-poster area
- Coffee breaks and lunches, according to the programme



## PAYMENT

All major credit cards are accepted (VISA, Mastercard/Eurocard, American Express).

### Bank details:

**Beneficiary:** AIM ITALY

**Bank:** Intesa San Paolo, Agenzia n. 6 - Viale Coni Zugna 62, 20144 Milano

**IBAN:** IT57D0306909457100000005623

**BIC:** BCITITMM

The payment transfer form should clearly state the name(s) of the delegate(s) and of the event "Lupus Meeting 2026".

Registration will be considered confirmed when the payment is received.

### Group Registration Procedure

The group registration procedure is available for a minimum of 2 participants and must be completed through the Company Area - Group Registration section.

The **early bird registration fee** will apply only if payment is received by the Organizing Secretariat **no later than 8 December 2025**, even if participant names have not been provided yet.

Between 9 December 2025 and 15 February 2026, the regular fee will apply to all group registrations that are not yet paid.

If payment is not received within the applicable fee deadline, the difference between the originally selected fee and the current applicable fee must be settled before registrations can be processed.

Participant names must be submitted online, and the group registration must be finalized **by 15 February 2026**. For any additional names submitted after this deadline, the on-site fee will apply.

## NAME CHANGES

**After 4 February 2026**, sponsors who wish to make name changes will be charged of a handling fee of € 70,00 (VAT 23% included) per name change. A new registration form for each replacement participant will be required before the name change can be processed. Individuals may make name changes only in exceptional cases.

## CANCELLATION POLICY

Notification of cancellation must be sent in writing to the organizing secretariat ([lupus2026@aimgroup.eu](mailto:lupus2026@aimgroup.eu)). Cancellations will be accepted until 4 February 2026, with a refund of all prepaid fees except for a 30% administration charge. No refunds will be made for cancellations received after this date.



### **Unexpected cancellation of the event or impossibility to hold it**

In the unlikely case that the 15th European Lupus Meeting cannot be held in whole or in part due to any event beyond the Organisers' control or force majeure (such as riot, fire, explosion, accident, flood, earthquake, sabotage, strikes, acts of any government, etc) the Congress Organisers cannot be held liable for any damage, cost, or loss incurred, such as registration fee, transportation and accommodation costs, or any other direct or indirect loss or consequential damage.

**ONLINE SERVICES WILL CLOSE ON 23 FEBRUARY 2026.**

### **SOCIAL MEDIA**

Follow us @SLEuroSociety

